Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological characteristics of four major histological types of high-grade parotid carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

High-grade parotid carcinoma generally has a poor prognosis, and the histological type is mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), carcinoma ex pleomorphic adenoma (CEPA), or adenoid cystic carcinoma (AdCC) in the majority of cases.

Methods

During the 23-year period from September 1999 to December 2022, 250 patients with parotid carcinoma underwent initial treatment and had the histopathological type of their carcinoma. Retrospective study evaluated 111 MEC, SDC, CEPA, or AdCC cases among 134 patients with high-grade parotid carcinoma. We examined pathological and clinical features and prognosis, evaluated factors associated with recurrence, and performed immunohistological examinations.

Results

Pathological and clinical features and factors associated with recurrence were different for each histological type. The 10-year disease-free survival rates were as follows: MEC, 34.9%; SDC, 22.6%; CEPA, 47.1%; and AdCC, 56.3%. Human epidermal growth factor receptor type-2 and androgen receptor were positive in 48% and 56% of patients with SDC, respectively, 38% and 25% of those with CEPA.

Conclusion

Each histological type has its own pathological and clinical features, recurrence types, and tumor activities, suggesting that differentiating between high-grade parotid carcinomas according to histological type will improve diagnosis, and thus prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Jeannon JP, Calman F, Gleeson M et al (2009) Management of advanced parotid cancer. A systematic review. Eur J Surg Oncol 35(9):908–915

    Article  PubMed  Google Scholar 

  2. Xiao CC, Zhan KY, White-Gilbertson SJ et al (2016) Predictors of nodal metastasis in parotid malignancies: a national cancer data base study of 22,653 patients. Otolaryngol Head Neck Surg 154(1):121–130

    Article  PubMed  Google Scholar 

  3. Westergaard-Nielsen M, Möller S, Godballe C et al (2021) Prognostic scoring models in parotid gland carcinoma. Head Neck 43(7):2081–2090

    Article  PubMed  Google Scholar 

  4. El-Naggar AK, Chan JKC, Grandis JR et al (2017) World health organization classification of tumours. Chapter 7, tumours of salivary glands. IARC Press, Lyon, pp 160–202

    Google Scholar 

  5. WHO Classification of Tumours Editorial Board (2022) Head and neck tumours, WHO classification of tumours series; vol 9, 5th edn. International Agency for Research on Cancer, Lyon

  6. Head and Neck Cancer Registry of Japan. http://www.jsnhc.umin.ne.jp

  7. Nishikado A, Kawata R, Haginomori SI et al (2018) A clinicopathological study of parotid carcinoma: 18-year review of 171 patients at a single institution. Int J Clin Oncol 23:615–624

    Article  PubMed  PubMed Central  Google Scholar 

  8. Goode RK, Auclair PL, Ellis AL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217–1224

    Article  CAS  PubMed  Google Scholar 

  9. Ellis GL, Auclair PL (1996) Tumours of the salivary glands, 3rd edn. Armed Forces Institute of Pathology, Washington, pp 173–196

    Google Scholar 

  10. Grasl S, Janik S, Faisal M et al (2023) Influence of grading on management and outcome in mucoepidermoid carcinoma of the parotid-A multi-institutional analysis. Laryngoscope 133(1):124–132

    Article  PubMed  Google Scholar 

  11. Antony J, Gopalan V, Smith RA et al (2012) Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 6(1):1–9

    Article  PubMed  Google Scholar 

  12. Gao M, Hao Y, Huang MX et al (2013) Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg 42:923–928

    Article  CAS  PubMed  Google Scholar 

  13. Zupancic M, Näsman A, Berglund A et al (2023) Adenoid cystic carcinoma (AdCC): a clinical survey of a large patient cohort. Cancers (Basel) 15(5):1499

    Article  PubMed  Google Scholar 

  14. Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006–1012

    Article  PubMed  PubMed Central  Google Scholar 

  16. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125(2):149–152

    Article  CAS  PubMed  Google Scholar 

  18. Khan AJ, DiGiovanna MP, Ross DA et al (2001) Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96(3):149–158

    Article  CAS  PubMed  Google Scholar 

  19. Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck–a 20 years experience. Int J Oral Maxillofac Surg 33(1):25–31

    Article  CAS  PubMed  Google Scholar 

  20. Szanto PA, Luna MA, Tortoledo ME et al (1984) Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54(6):1062–1069

    Article  CAS  PubMed  Google Scholar 

  21. Spiro RH, Huvos AG (1992) Stage means more than grade in adenoid cystic carcinoma. Am J Surg 164(6):623–628

    Article  CAS  PubMed  Google Scholar 

  22. Flynn MB, Maguire S, Martinez S et al (1999) Primary squamous cell carcinoma of the parotid gland: the importance of correct histological diagnosis. Ann Surg Oncol 6(8):768–770

    Article  CAS  PubMed  Google Scholar 

  23. Pfister DG, Spencer S, Adelstein D et al (2020) Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 18(7):873–898

    Article  Google Scholar 

  24. Geiger JL, Ismaila N, Beadle B et al (2021) Management of salivary gland malignancy: ASCO guideline. J Clin Oncol 39(17):1909–1941

    Article  PubMed  Google Scholar 

  25. Zbären P, Nuyens M, Loosli H et al (2004) Diagnostic accuracy of fine-needle aspiration cytology and frozen section in primary parotid carcinoma. Cancer 100(9):1876–1883

    Article  PubMed  Google Scholar 

  26. Nishikawa S, Kawata R, Higashino M et al (2015) Assessing the histological type and grade of primary parotid carcinoma by fine-needle aspiration and frozen section. Auris Nasus Larynx 42(6):463–468

    Article  PubMed  Google Scholar 

  27. Kashiwagi N, Murakami T, Chikugo T et al (2012) MRI findings of mucoepidermoid carcinoma of the parotid gland: correlation with pathological features. Br J Radiol 85:709–713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nakaguro M, Tada Y, Faquin WC et al (2020) Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol 128(10):693–703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dalin MG, Watson PA, Ho AL et al (2017) Androgen receptor signaling in salivary gland cancer. Cancers (Basel) 9(2):17

    Article  PubMed  Google Scholar 

  30. Takahashi H, Tada Y, Saotome T et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37(2):125–134

    Article  CAS  PubMed  Google Scholar 

  31. Fushimi C, Tada Y, Takahashi H et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979–984

    Article  CAS  PubMed  Google Scholar 

  32. Mukaigawa T, Hayashi R, Hashimoto K et al (2016) Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol 114(1):36–43

    Article  CAS  PubMed  Google Scholar 

  33. Even C, Delord JP, Price KA et al (2022) Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 171:259–268

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan

    Ryo Kawata, Ichita Kinoshita, Tsuyoshi Jinnin, Masaaki Higashino & Tetsuya Terada

  2. Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan

    Yoshitaka Kurisu & Yoshinobu Hirose

  3. Institutional Research Office, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan

    Takeshi Tochizawa

Authors
  1. Ryo Kawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ichita Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsuyoshi Jinnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaaki Higashino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Terada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Kurisu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshinobu Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Tochizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RK designed and supervised the study. IK, TT and RK wrote the manuscript. TJ, MH, IK and TT acquired all clinical data. YK, and YH assisted in the pathological analyses. TT assisted in statistical analyses. All authors performed data analysis and interpretation, and approved the manuscript.

Corresponding author

Correspondence to Ryo Kawata.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study was reviewed and approved by the ethics committee of Osaka Medical and Pharmaceutical University (approval number #2621).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawata, R., Kinoshita, I., Jinnin, T. et al. Clinicopathological characteristics of four major histological types of high-grade parotid carcinoma. Int J Clin Oncol 28, 1597–1606 (2023). https://doi.org/10.1007/s10147-023-02416-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02416-9

Keywords

Search

Navigation